Harmony Biosciences Holdings Inc (NAS:HRMY)
$ 34.2 -0.52 (-1.5%) Market Cap: 1.95 Bil Enterprise Value: 1.75 Bil PE Ratio: 16.21 PB Ratio: 3.27 GF Score: 65/100

Harmony Biosciences Holdings Inc at Piper Sandler Healthcare Conference (Virtual)- Pre-recorded Firside Chat Transcript

Nov 30, 2020 / 01:35PM GMT
Release Date Price: $43.25 (-8.93%)
David A. Amsellem
Piper Sandler & Co., Research Division - MD & Senior Research Analyst

Hi, this is David Amsellem from the Piper Sandler specialty pharma team, and we will be spending the next 25 minutes or so chatting with Harmony Biosciences. And with us is CEO, John Jacobs. John, thanks very much for joining us.

I wanted to flip it over to you, John, for some quick introductory remarks, and then we can dive right in to what will be a lively discussion given the launch of WAKIX. So John, why don't you take it away?

John Charles Jacobs
Harmony Biosciences Holdings, Inc. - President, CEO & Director

David, first of all, thank you for the nice introduction, and we appreciate this opportunity to share a little bit more color and context on our launch of WAKIX with Harmony. Our company, for those of you who are new to our story, we were founded in October of 2017. And since then, we built out a company of over 150 employees, and we've launched our first product in the U.S. Market, WAKIX. And we're starting with WAKIX in narcolepsy, although

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot